Terumo BCT

UNLOCKING THE POTENTIAL OF BLOOD

[ { "thumbSrc": "/PublishingImages/carousel/CSR-Report-thumb.gif", "imgSrc": "/PublishingImages/carousel/CSR-Report.jpg", "linkSrc": "/about-us/corporate-responsibility", "color": "#009a44", "title1": "Global Connection:", "description1": "Learn About Our", "description2": "Commitment to Social Responsibility" }, { "thumbSrc": "/_catalogs/masterpage/dotcom/img/carousel/thumbs/immuno.jpg", "imgSrc": "/PublishingImages/carousel/immuno.jpg", "linkSrc": "/cell-therapy-technologies/immunotherapy", "color": "#ff7900", "title1": "Immunotherapy:", "description1": "", "description2": "Enabling Next-Generation Cancer Treatments" }, { "thumbSrc": "/_catalogs/masterpage/dotcom/img/carousel/thumbs/ts.jpg", "imgSrc": "/PublishingImages/carousel/ts.jpg", "linkSrc": "/therapeutic-apheresis", "color": "#aa6dab", "title1": "Advancing Apheresis:", "description1": "", "description2": "More Treatment Options for More Patients" }, { "thumbSrc": "/_catalogs/masterpage/dotcom/img/carousel/thumbs/contract-manufacturing.jpg", "imgSrc": "/PublishingImages/carousel/contract-manufacturing.jpg", "linkSrc": "/contract-manufacturing", "color": "#447ebc", "title1": "Contract Manufacturing:", "description1": "", "description2": "Only the Right Team and the Right Facility Will Do" }, { "thumbSrc": "/_catalogs/masterpage/dotcom/img/carousel/thumbs/bcs-sw.jpg", "imgSrc": "/PublishingImages/carousel/bcs-sw.jpg", "linkSrc": "/blood-center-services", "color": "#447ebc", "title1": "The Power to Perform", "description1": "", "description2": "Helping Blood Centers With Their Toughest Challenges" } ]

QUICK LINKS

Get Product Support Find Technical Documents Find Certificates of Compliance Get Training Start a Career With Us

LATEST NEWS

David Perez to Retire as President and CEO of Terumo BCT on March 31, 2019; Antoinette Gawin Named Successor

New Collaboration With StafaCT Will Optimize Patient Pathways for Cellular Treatments

Collaborative Global Effort to Advance Blood Safety Moves Forward Across Ghana

Terumo BCT's Spectra Optia^® Apheresis System is the First and Only Device on the European Market Indicated to Treat Guillain-Barré Syndrome and Myasthenia Gravis Using Therapeutic Plasma Exchange